Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
Objectives To investigate the clinical characteristics, survival and prognosis of patients with multiple myeloma (MM) and head extramedullary plasmacytoma (EMP). Methods Forty MM patients were enrolled in the study (18 men, 22 women; median age, 55 years). Results Median overall survival (OS) and progression-free survival (PFS) were 24 (5-78) months and 17 (2-36) months, respectively. The 2-, 3- and 5-year OS rates were 51%, 20% and 7%, respectively. The 2-year PFS was 15%. Median OS and PFS in patients administered velcade were 26 (18-50) and 22.5 (5-78) months, compared with 20 (10-30) and 13.5 (2-36) months in patients without velcade, respectively. Median OS was 23.5 (5-50) months in patients with EMP at MM diagnosis ( n = 25) and 36 (22-78) months in patients with head EMP diagnosed during the disease course ( n = 15). Sixteen MM patients had EMP invasion of the head only and 24 had invasion at multiple sites. Median OS was 25 (22-78) months in patients with EMP of the head only and 22 (5-78) months in patients with EMP invasion at multiple sites. Conclusion MM patients with head EMP show a more aggressive disease course and shorter OS and PFS. The prognosis of these patients is poor, especially in patients with head EMP at MM diagnosis, though combined chemotherapy and radiotherapy may prolong survival.
1 Department of Haematology, PLA Rocket Forces General Hospital, Beijing, China.
Wan-Jun
WJ
Sun
2 Department of Haematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Jia-Jia
JJ
Zhang
2 Department of Haematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Na
N
An
2 Department of Haematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Men
M
Shen
2 Department of Haematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Zhong-Xia
ZX
Huang
2 Department of Haematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Xin
X
Li
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000069286:Bortezomib / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D018450:Disease Progression; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D010950:Plasma Cells / Q000187:drug effects / Q000473:pathology*; D010954:Plasmacytoma / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
D000970:Antineoplastic Agents; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin; C027260:pirarubicin; D007069:Ifosfamide
Head extramedullary plasmacytoma; multiple myeloma; prognosis; survival